210 likes | 224 Views
Explore genetic testing techniques, recent clinical trials, off-label treatments, and faculty experiences with ALK inhibitors in this program. Learn about ongoing front-line trials and potential use of immunotherapy.
E N D
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Summary of Trials in Crizotinib-Refractory ALK-Positive NSCLC